Revision as of 00:37, 28 August 2020

Section editor
	Ronald S. Go, MD Mayo Clinic Rochester, MN

1 regimens on this page 1 variants on this page

Guidelines

2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease PubMed

back to top

Study	Evidence
Diamond et al. 2019 (MSK 15-216)	Pilot, <20 pts in this arm

Note: there were N=2 patients with this type of histiocytosis.

28-day cycles

MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains verified protocol link to PMC article PubMed

@@ Line 32: / Line 32: @@
 |}
 ''Note: there were N=2 patients with this type of histiocytosis.''
-====Chemotherapy====
+====Targeted therapy====
 *[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21
 '''28-day cycles'''
 ===References===
 # '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://www.nature.com/articles/s41586-019-1012-y link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30867592 PubMed]